GigaGen

Giga Gen

Biotechnology, 407 Cabot Rd, San Carlos, California, 94080, United States, 11-50 Employees

gigagen.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 41********

Who is GIGAGEN

GigaGen, a subsidiary of Grifols, is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, si...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GIGAGEN

GigaGen Org Chart and Mapping

Carter Keller

Chief Executive Officer

Employees

Shayna Lee

Senior Office Manager

Tess Weinberger

Senior Research Associate

Adam Adler

Chief Scientific Officer

Jan Simons

Senior Director of Technology

Juan Sanchez

Research Associate, Process Development

Erica Stone

Vice President, Oncology

Catherine Medina

Vice President, Operations

Ilana Segal

Senior Research Associate

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding GigaGen

Answer: GigaGen's headquarters are located at 407 Cabot Rd, San Carlos, California, 94080, United States

Answer: GigaGen's phone number is 41********

Answer: GigaGen's official website is https://gigagen.com

Answer: GigaGen's revenue is $1 Million to $5 Million

Answer: GigaGen's SIC: 2836

Answer: GigaGen's NAICS: 541714

Answer: GigaGen has 11-50 employees

Answer: GigaGen is in Biotechnology

Answer: GigaGen contact info: Phone number: 41******** Website: https://gigagen.com

Answer: GigaGen, a subsidiary of Grifols, is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. GigaGens novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases. GigaGens lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access